Author

Amber Jessup

Observed name: Amber I. Jessup

Institutions: United States Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Inspector General

Observed institutions: Center for Food Safety and Applied Nutrition, United States Department of Health and Human Services, United States Food and Drug Administration, Harvard University, Cornell University, Office of the Assistant Secretary for Planning and Evaluation, Office of Inspector General, Department of Health and Human Services

OpenAlex ID: A5068260915

Economics of Food Labeling

2001 · Elise Golan, Fred Kuchler, et al. · Journal of Consumer Policy · 416

Key cost drivers of pharmaceutical clinical trials in the United States

2016 · Aylin Sertkaya, Hui-Hsing Wong, et al. · Clinical Trials · 404

Costs of Drug Development and Research and Development Intensity in the US, 2000-2018

2024 · Aylin Sertkaya, Trinidad Beleche, et al. · JAMA Network Open · 247

Estimated Cost of Developing a Therapeutic Complex Medical Device in the US

2022 · Aylin Sertkaya, Rebecca DeVries, et al. · JAMA Network Open · 69

Valuing avoided morbidity using meta‐regression analysis: what can health status measures and QALYs tell us about WTP?

2006 · George Van Houtven, John Powers, et al. · Health Economics · 38

Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey

2021 · Allison R. Kolbe, Aaron Kearsley, et al. · BioDrugs · 34

Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users

2021 · Ariel Dora Stern, Jacqueline L. Chen, et al. · Health Affairs · 32

Economic Approaches to Estimating Benefits of Regulations Affecting Addictive Goods

2016 · David M. Cutler, Amber I. Jessup, et al. · American Journal of Preventive Medicine · 28

Valuing Regulations Affecting Addictive or Habitual Goods

2015 · David M. Cutler, Amber Jessup, et al. · Journal of Benefit-Cost Analysis · 27

Valuation of Morbidity Losses: Meta-Analysis of Willingness-to-Pay and Health Status Measures

2003 · Amber Jessup · 10

Assessing the state of antibacterial drug discovery through patent analysis

2023 · Aylin Sertkaya, J. Daniel McGeeney, et al. · International Journal of Antimicrobial Agents · 5

Promoting Antibacterial Drug Development: Select Policies and Challenges

2016 · Aylin Sertkaya, Amber Jessup, et al. · Applied Health Economics and Health Policy · 5

Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States

2018 · Aylin Sertkaya, Hui-Hsing Wong, et al. · American Journal of Infection Control · 4

Evaluating Chronic Disease for Heterogeneous Populations

2007 · Robert L. Scharff, Amber Jessup · Medical Care · 2

Analytical Framework for Examining the Value of Antibacterial Products

2014 · Amber Jessup, Hui–Hsing Wong

Animal-Derived Cosmetic Ingredient Database

2002 · Amber Jessup, Robert Beach, et al.

Works count: 16

Citation count: 1,321

H-index: 10

I10-index: 10